Corrigendum: A TNFR2-specific TNF fusion protein with improved in vivo activity

Front Immunol. 2023 Dec 18:14:1352525. doi: 10.3389/fimmu.2023.1352525. eCollection 2023.

Juan Gamboa Vargas^#^{1

2}, Jennifer Wagner^#³, Haroon Shaikh^{1

2}, Isabell Lang³, Juliane Medler³, Mohamed Anany^{3

4}, Tim Steinfatt¹, Josefina Peña Mosca^{1

2}, Stephanie Haack¹, Julia Dahlhoff¹, Maike Büttner-Herold⁵, Carolin Graf¹, Estibaliz Arellano Viera¹, Hermann Einsele¹, Harald Wajant^#³, Andreas Beilhack^#^{1

2}

¹ Interdisciplinary Center for Clinical Research Laboratory, Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany.
² Graduate School of Life Sciences, Würzburg University, Würzburg, Germany.
³ Division of Molecular Internal Medicine, Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany.
⁴ Department of Microbial Biotechnology, Institute of Biotechnology, National Research Center, Giza, Egypt.
⁵ Department of Nephropathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.

^# Contributed equally.

Abstract

[This corrects the article DOI: 10.3389/fimmu.2022.888274.].

Keywords: GvHD; TNF; TNFR2; agonist; regulatory T cells; serum retention.